Pramlintide: indexed trial records

This page carries 12 of the 484 records the literature query returned for Pramlintide, selected by citation count and preferring records that name the compound in their title. It is a selection, not a complete index.

Every row below resolves to a real identifier and names the study model the indexer assigned. The record class is read from the publication type on the record itself. Nothing here states what a record found.

At a glance

Class

Amylin and amylin receptor agonists

Receptor targets as recorded

Amylin receptor

Records indexed here

12

Records returned by the query

484

Publication years covered

2008–2021

Query retrieved

2026-10-12

Shape of the indexed record set

Study model is the indexer’s own assignment, taken from the MeSH population headings and the publication type. It is not a judgement about how well a record was conducted.

Endpoint coverage

Derived record-set tier

Human trial evidence (INFERRED, derived from record counts)
Basis: 7 of 12 indexed records are interventional human trials by their own assigned publication type.
This label counts record types. It is not an assessment of clinical efficacy, of safety, of study quality or of consensus, and it does not rank one compound above another.

What the corpus does not carry for this compound

• Identity fields with no source retrieved: uniprot_id, sequence.
• Reported half-life: no source retrieved, so the value reads Unknown.
• Amounts reported in the cited literature: no row recorded.
• Adverse effects reported in the cited literature: no row recorded.
• Long-form mechanism: not written, because no source was read in full.
• Records the query returned that this corpus does not carry: 472.

An absent row records the absence of a retrieved report, never the absence of the thing itself.

Application register

A query of the FDA Drugs@FDA application register on 2026-10-09 returned 1 application record(s) for this compound name (including NDA021332, marketed as SYMLIN). Material supplied as a research chemical is not the subject of those applications and is not an FDA-approved product.^[2]

Scope statement: this records the result of a single automated query against the openFDA drugsfda endpoint on the stated date. It is not legal advice and is not a jurisdiction-by-jurisdiction legality assessment.

The records

Where this page sits

Receptor targets

• Amylin receptor: every compound in scope acting at it

All compounds in scope: the trial index. Coverage by endpoint: the endpoint index.

Review status

Review tier

High impact

State

Pending qualified review

Compiled by

automated pipeline

Qualified clinical review

None on record

Why this tier was assigned

• the name carries 1 Drugs@FDA application record(s), so readers may conflate it with an approved medicine
• 7 indexed record(s) are interventional human trials
• the class covers weight-management and metabolic prescribing, the highest-risk consumer subject in this corpus

Checks the pipeline performed

• every cited source id resolves to a sources[] row on the entity
• every identifier is a well-formed PMID or DOI
• study model derived only from assigned MeSH headings and publication types
• banned-phrase lint over rendered HTML including title, meta, alt and JSON-LD
• unknown values render as the literal word Unknown

Checks the pipeline did not perform

• no full text was read
• no clinical appraisal of any study
• no assessment of whether the indexed set is representative of the literature

A high_impact profile with qualified_review null must not be published as indexable. Compilation and linting are not clinical validation.

Sources

1. PubChem Compound Summary for CID 70691388, Pramlintide. PubChem, National Library of Medicine (2026). pubchem:70691388
2. Drugs@FDA application register query for this compound, 1 application(s) returned: NDA021332. U.S. Food and Drug Administration, openFDA drugsfda endpoint (2026). fda:pramlintide
3. Amylin replacement with pramlintide as an adjunct to insulin therapy in type 1 and type 2 diabetes mellitus: a physiological approach toward improved metabolic control. Current pharmaceutical design (2001). pmid:11472273
4. A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes. Diabetes care (2002). pmid:11919132
5. Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial. Diabetes care (2003). pmid:12610038
6. Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial. Diabetic medicine : a journal of the British Diabetic Association (2004). pmid:15498087
7. A double-blind, placebo-controlled trial assessing pramlintide treatment in the setting of intensive insulin therapy in type 1 diabetes. Diabetes care (2006). pmid:17003291
8. Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated subjects with type 2 diabetes. Diabetes technology & therapeutics (2002). pmid:12017421
9. Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients. Obesity research (2004). pmid:15090634
10. Effect of pramlintide on satiety and food intake in obese subjects and subjects with type 2 diabetes. Diabetologia (2005). pmid:15843914
11. Progressive reduction in body weight after treatment with the amylin analog pramlintide in obese subjects: a phase 2, randomized, placebo-controlled, dose-escalation study. The Journal of clinical endocrinology and metabolism (2007). pmid:17504894
12. Sustained weight loss following 12-month pramlintide treatment as an adjunct to lifestyle intervention in obesity. Diabetes care (2008). pmid:18753666
13. Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy. Obesity (Silver Spring, Md.) (2009). pmid:19521351